Polyvinylpyrrolidone-Capped Silver Nanoparticle Inhibits Infection of Carbapenem-Resistant Strain of Acinetobacter baumannii in the Human Pulmonary Epithelial Cell

Acinetobacter baumannii, an opportunistic ESKAPE pathogen, causes respiratory and urinary tract infections. Its prevalence increases gradually in the clinical setup. Pathogenicity of Acinetobacter is significantly influenced by its ability to infect and survive in human pulmonary cells. Therefore, it is important to study the infection of A. baumannii in human pulmonary host cell (A-549), monitoring surface interacting and internalized bacteria. It was found that during infection of A. baumannii, about 40% bacteria adhered to A-549, whereas 20% got internalized inside pulmonary cell and induces threefold increase in the reactive oxygen species production. We have synthesized polyvinylpyrrolidone (PVP)-capped AgNPs using chemical methods and tested its efficacy against carbapenem-resistant strain of A. baumannii. PVP-capped silver nanoparticles (PVP-AgNPs) (30 µM) have shown antibacterial activity against carbapenem-resistant strain of A. baumannii and this concentration does not have any cytotoxic effect on the human pulmonary cell line (IC50 is 130 µM). Similarly, PVP-AgNPs treatment decreases 80% viability of intracellular bacteria, decreases adherence of A. baumannii to A-549 (40 to 2.2%), and decreases intracellular concentration (20 to 1.3%) of A. baumannii. This concludes that PVP-AgNPs can be developed as a substitute for carbapenem to control the infection caused by carbapenem-resistant A. baumannii.

Acinetobacter is significantly influenced by its ability to survive in the human pulmonary cells. Therefore, it is important to study the interaction of A. baumannii with human pulmonary host cell.
AgNPs (silver nanoparticles) have antimicrobial property against diverse microbes, probably due to their different mechanisms of antimicrobial action (11,12). Polyvinylpyrrolidone (PVP) is a neutral stabilizer and less sensitive to surface charge screening processes like pH change and ionic strength (13). Recent reports have shown that PVP-capped AgNPs are more stable than other AgNPs (14,15). PVP-capped AgNPs are also less toxic to the mammalian cells (16). Likewise, interaction of PVP-capped silver nanoparticles (PVP-AgNPs) with serum proteins affects its in vivo antimicrobial activity. It has been reported that PVP-capped AgNPs have better in vivo antimicrobial activity than other capped AgNPs (17). Hence, they can be used as a substitute to the carbapenem. Therefore, in the present study, we have monitored the infection of carbapenem-resistant strain of A. baumannii to the human pulmonary (alveolar epithelial) cell line A-549. Further, we have also monitored the surface interacting and internalized bacteria and tested the efficacy of PVP-capped AgNPs on the infection of A. baumannii in A-549 cell line. The present result might help to understand the infection caused by A. baumannii to human pulmonary cell as well as control of infection caused by it using the PVP-capped silver nanomaterial.

Bacterial strain
All the work related to cell line and bacteria were performed aseptically, under laminar airflow. Clinical strain RS-307 of A. baumannii was grown in Luria-Bertani broth (LB) media at 37°C till it reached optical density to 0.6 OD. After sufficient bacterial growth, streaking was done on the Luria agar plate to isolate the single bacterial colony. Single colony was used for suspension culture. Prior to coinfection, bacterial culture was centrifuged and re-suspended in PBS to remove deleterious effects of toxins (cytotoxins) present in the culture.
human Pulmonary cell line culture The human alveolar basal epithelial cell line A-549 (purchased from Cell repository, NCCS, Pune) was cultured in high glucose Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum albumin (heat inactivation was performed at 56°C for 30 min), amphotericin B (2.5 µg/ml), vancomycin (50 µg/ml), gentamicin (50 µg/ml), and 1% HEPES in a humidified, 5% CO2 at 37°C. Passage of A-549 human pulmonary cell line in 25 cm 2 flask was done after every 2-3 days intervals when they were confluent. The cells were seeded for 24 h in 96 well plates for MTT and LDH assay and 6-well plates for coinfection with the A. baumannii.

Preparation of cell line and Bacterial culture for infection
Confluent A-549 cells flask was washed twice with PBS buffer (pre-warm at 37°C). The cells were detached with the help of 0.05% trypsin-EDTA and complete media was added. The suspension was centrifuged and cells pellet were re-suspended in the fresh DMEM medium containing 10% fetal bovine serum without antibiotics, at a concentration of 2 × 10 5 cells/ml. Simultaneously, bacterial culture was inoculated in 100 ml of LB broth and was grown at 37°C with vigorous shaking (180 rpm) till optical density reached to 0.6. We have counted colony-forming unit (CFU) of the bacteria before coinfection.
infection of a-549 cells by rs-307 strain of A. baumannii A-549 cells were grown at 37°C in 5%CO2 till they reached at least 90% confluency without contamination. The cells were washed with pre-warm PBS. 1 ml of fresh medium supplemented with 10% serum without antibiotics was added to each well. The control wells were prepared by adding fresh medium without A-549 cells in three wells. These wells were used as a blank for addition of bacterial strains. Coinfection was achieved by adding an aliquot of each bacterial culture to each well containing A-549 cells (in triplicate) and in the blank. This coinfection represents MOI (multiplicity of infection) of 3:1 (bacteria, 1.2 × 10 7 : cells, 0.4 × 10 7 ). Infected A-549 cells were incubated in incubator for 24 h at 37°C with 5% CO2.

cFU counting of Different stages of the infections
We have counted bacterial populations of four different stages of infection, i.e., before coinfection, remain non-interact during coinfection (suspension culture in DMEM media which contain the free bacteria), interacting or adhered bacteria on the surface of A-549 (which were isolated after mixing of cell pellet in the PBS and centrifugation, as explained in next section) and internalized bacteria into A-549 (which were isolated after homogenization). The CFU was determined for above four stages.

Protein extraction
After 24 h incubation, washing was done 3 times with pre-warm PBS. 1 ml of PBS (containing 0.1 mM protease inhibitor PMSF) was added. Adhered bacteria were detached and centrifuged at 3000g for 5 min to separate the loosely adhered bacteria. The pellet was dissolved in 1 ml PBS (with 0.1 mM PMSF). The dissolved pellet was homogenized for 1 min. Homogenized sample were centrifuged at 7000g for 10 min. The supernatant was stored at −80°C containing A-549 cell lines proteins. The pellet (containing internalized bacteria) was suspended in 1 ml PBS with 0.1 mM PMSF. This suspended pellet was sonicated for three cycles of 30 s (20 kHz, 130 W) with the interval of 1 min. The sonicated samples were centrifuged at 10000g for 10 min. The supernatant contained bacterial protein and was stored at −80°C. The samples were collected before homogenization and sonication, and used for bacterial CFU counting that represent adhered and internalized bacteria, respectively. Protein concentrations were measured for bacterial samples (internalized and adhere) and cell line (before and after bacterial infection) using Bradford methods.

Preparation of PVP-capped agnPs and In Vitro antimicrobial activity Test
Polyvinylpyrrolidone-capped AgNPs were prepared as per our published methods (12). The size and zeta-potential of synthesized PVP-capped AgNPs were monitored using dynamic light scattering-based particle analyzer. In vitro susceptibility of PVP-AgNPs (30 µM) was performed on carbapenem-resistant strain of A. baumannii using disc diffusion assay and growth kinetics analysis as per our published protocol (18).

Treatment of PVP-capped agnPs and cFU counting for Different stages of the infections
For the treatment, four T-25 flasks were prepared. First flask was used as a control for cell line, second flask was used for bacterial infection, third flask was for AgNPs treatment after bacterial infection, and fourth flask as negative control for AgNPs treatment. All four flasks were incubated at 37°C for 24 h with 5% CO2. Coinfection was achieved by adding 1.2 × 10 7 CFU that represents MOI of 3:1 (bacteria, 1.2 × 10 7 : cells, 0.4 × 10 7 ). Infected A-549 cells were incubated in the CO2 incubator at 37°C for 24 h with 5% CO2. 500 µl of culture media was taken for counting non-interacting bacteria. The media was discarded gently and flasks were washed mildly two times by

resUlTs
The adherence and persistence ability of A. baumannii on the host cell is central to its pathogenicity. To cause host cell infections, bacteria first colonize on the surface of the host. They express different types of adhesin molecules for attachment to host cells. These adhesins bind the surface soluble proteins of the host and act as a bridge between host and bacteria. Adherence is the first most important step than invasion and secretion of toxins. Adhered bacteria invade into the host cell and causes infection. In this study, we have used RS-307 strain of A. baumannii, which is a multidrug resistant strain of A. baumannii and have high MIC (>64 μg/ml) for imipenem (a carbapenem), and A-549 cell line, which is a human pulmonary (alveolar epithelial) cells. This cell line has been chosen as A. baumannii causes pneumonia that is associated with lungs.    Figure 1. The infection of A-549 cell line with the A. baumannii leads to the lysis of the A-549 cell lines and also changes the morphology of A-549 cell lines that can be seen in Figure 2.

In Vitro susceptibility of carbapenemresistant A. baumannii against PVPcapped agnPs
Synthesized PVP-capped AgNPs have maximum absorbance peak around 400 nm for AgNPs ( Figure 3A) and size of 133 nm with polydispersity index of 23% ( Figure 3B). Similarly, zeta-potential of nanoparticle was found to be −34 mV. Growth kinetics of RS-307 strain of A. baumannii was determined in the absence and presence (30 µM) of PVP-capped AgNPs. Optical density was measured at 605 nm at an interval of 30 min using UV-Vis spectrophotometer. Growth curves were prepared using absorption data. The experiment was performed in triplets for untreated and treated samples and average value was used to prepare the plot. Relative growth curves were prepared for comparison purpose. The result showed that PVP-capped AgNPs showed good antimicrobial activity against carbapenem-resistant strain of A. baumannii (Figure 3C).
cytotoxicity Test of PVP-capped agnPs on a-549 confirm its non-Toxic nature at its inhibitory concentration The cytotoxic effect of PVP-capped AgNPs on the human pulmonary epithelial cell lines (A-549) was identified using MTT Assay and LDH assay. Figure 4 showed that the concentration at which it showed bactericidal activity has no cytotoxicity. The IC50 value for PVP-AgNPs against A-549 cell line was found to be 130 µM, which is four times higher than the concentration showing antimicrobial activity. The 30 µM PVP-AgNPs also does not have hemolytic activity.

PVP-capped agnPs Prevent a-549 cell line cell Death induced by A. baumannii
The infected cell line of A-549 was treated with PVP-AgNPs. The infection leads to the death of A-549 cell line ( Figure 5B) but PVP-AgNPs protects pulmonary cell line (A-549) from the infection of A. baumannii ( Figure 5C). The morphologies of PVP-capped AgNPs-treated A-549 cell line ( Figure 5C) are very similar to the uninfected cell lines ( Figure 5A). Therefore, it can be suggested that presence of PVP-AgNPs prevent infection of carbapenem-resistant strain of A. baumannii in A549 cell line.

PVP-capped agnPs Decreases attachment and internalization of A. baumannii into a-549
Colony-forming unit counting in the absence and presence of PVP-AgNPs showed that PVP-AgNPs reduce the number of surface attached bacteria from about 40 to 2.2%. The number of intracellular bacteria was also reduced from 18 to the 1.25%.
Therefore, we can say that PVP-AgNPs reduces the attachment and internalization of A. baumannii on the pulmonary cell model.    rOs Production by a549 cell line after

A. baumannii infection
Reactive oxygen species are used by pulmonary epithelial cells against pathogens (19). ROS can kill pathogens (such as A. baumannii) directly by causing oxidative damage to biomolecules or indirectly by stimulating pathogen elimination by various non-oxidative mechanisms (19). Therefore, we have monitored the ROS production during the infection as well as treatment. Result (Figure 6) showed that A. baumannii infection promotes threefold increase (OD at 620 nm is 0.83 for infected and 0.27 for uninfected) in the production of ROS. This is correlated with the previous result, which showed that ROS production increases in pulmonary epithelial cells after bacterial infection. The treatment of PVP-AgNPs shifted the ROS level to normal, which also confirms that approximately all the intracellular bacteria were killed by PVP-AgNPs. The result is correlated with the bacterial viability assay, which also confirms that about 80% intracellular bacteria were killed by the PVP-AgNPs.

PVP-capped agnPs Treatment changes the sDs Protein Profiling
The

DiscUssiOn
Acinetobacter baumannii is a Gram-negative multi drug-resistant bacterium causing nosocomial infection. Emergence of drug resistance in A. baumannii will lead to the high mortality and morbidity. Therefore, it is a high time to develop an alternative drug against carbapenem-resistant strain of A. baumannii. There are different approaches including herbal-based (5, 20, 21), nanomaterial-based (12,22) and combination therapy (23)(24)(25)(26)(27)(28)(29), which have been tried recently against A. baumannii and few of them have shown very promising results. Silver nanoparticles have recently emerged as antimicrobial agents for treating bacterial infections. PVP-capped AgNPs (11,12) and citrate-capped AgNPs (22) were found to inhibit the growth of A. baumannii. Interaction of AgNPs with different cell models and their cellular effect have been reviewed recently (30) and showed the involvement of ROS during interaction of AgNPs with different cell lines. Recently, it is also reported that acinetin-505, a small lipopeptide-like compound, have role in the interaction of A. baumannii with pulmonary cells model (31). Most of the studied done so far have highlighted the use of AgNPs against A. baumannii in suspension form but less have been studied about the inhibitory role of AgNPs in the infection of A. baumannii to the human cell model. Therefore, we have chemically synthesized PVP-capped AgNPs and characterized them for size and zeta-potential. The results confirm the formation of PVP-capped AgNPs with size around 100 nm. Synthesized nanoparticles were found active against carabpenem-resistant strain of A. baumannii, hence further used for its effect during infection of A. baumannii to human pulmonary cells model. Result of coinfection showed that A. baumannii leads to the death of basal epithelial cell line, i.e., A-549 and infection of A. baumannii to human pulmonary cells was inhibited by PVP-AgNPs. Similarly, PVP-AgNPs have no or very less cytotoxic effect at the bacterial inhibitory concentration. Likewise, it was also seen that there is a decrease of 80% viability of the intracellular bacteria. Therefore, present study suggest that PVP-AgNPs can be developed as a good alternative to carbapenem (beta-lactam), which inhibit the growth of carbapenem-resistant strain of A. baumannii. cOnclUsiOn Acinetobacter baumannii causes pneumonia via targeting human pulmonary cells. Hence, human alveolar basal epithelial cell line A-549 was selected as a model to study the infection caused by A. baumannii. The present study concludes that during infection of A. baumannii about 40% bacteria adhere to the surface of A549 while about 20% get internalized inside the pulmonary cell line. We have also seen that during Acinetobacter infection, ROS concentration was found to increase by threefold. We have synthesized PVP-capped AgNPs using chemical methods and tested its efficacy against carbapenem-resistant strain of A. baumannii. The result showed that 30 µM PVP-AgNPs inhibit growth of A. baumannii in in vitro experiments. We have also shown that this concentration of PVP-AgNPs does not show any cytotoxic effect on the human pulmonary cell line with IC50 value of 130 µM. The PVP-AgNPs treatment causes about 80% decrease in the viability of the intracellular bacteria. Therefore, based on the result of the present study it can be concluded that PVP-capped silver nanoparticle can be a suitable replacement to the current antibiotics used against A. baumannii. Pulmonary cell targeted delivery of PVP-AgNPs in animal model can be further studied to use this molecule as a suitable drug against A. baumannii.